Search Results - "Sathiyaseelan, Thillainaygam"

An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes by Alleva, David G, Delpero, Andrea R, Sathiyaseelan, Thillainaygam, Murikipudi, Sylaja, Lancaster, Thomas M, Atkinson, Mark A, Wasserfall, Clive H, Yu, Liping, Ragupathy, Ramya, Bonami, Rachel H, Zion, Todd C

“…The antigen-presenting cell function of insulin-reactive B cells promotes type 1 diabetes (T1D) in non-obese diabetic (NOD) mice by stimulating pathogenic T…”
Get full text

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine by Alleva, David G., Feitsma, Eline A., Janssen, Yester F., Boersma, Hendrikus H., Lancaster, Thomas M., Sathiyaseelan, Thillainaygam, Murikipudi, Sylaja, Delpero, Andrea R., Scully, Melanie M., Ragupathy, Ramya, Kotha, Sravya, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Ronca, Shannon E., Green, Freedom M., Shaw, Stephen A., Aminetzah, Ari, Kruijff, Schelto, Brom, Maarten, van Dam, Gooitzen M., Zion, Todd C.

“…AKS-452, a subunit vaccine comprising an Fc fusion of the ancestral wild-type (WT) SARS-CoV-2 virus spike protein receptor binding domain (SP/RBD), was…”
Get full text

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452 by Alleva, David G., Delpero, Andrea R., Scully, Melanie M., Murikipudi, Sylaja, Ragupathy, Ramya, Greaves, Emma K., Sathiyaseelan, Thillainaygam, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Lancaster, Thomas M., Webb, Sarah S., Jasa, Allison I., Ronca, Shannon E., Green, Freedom M., Elyard, Hanne Andersen, Yee, JoAnn, Klein, Jeffrey, Karnes, Larry, Sollie, Frans, Zion, Todd C.

“…AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and…”
Get full text

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452 by Feitsma, Eline A., Janssen, Yester F., Boersma, Hendrikus H., van Sleen, Yannick, van Baarle, Debbie, Alleva, David G., Lancaster, Thomas M., Sathiyaseelan, Thillainaygam, Murikipudi, Sylaja, Delpero, Andrea R., Scully, Melanie M., Ragupathy, Ramya, Kotha, Sravya, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Ronca, Shannon E., Green, Freedom M., Aminetzah, Ari, Sollie, Frans, Kruijff, Schelto, Brom, Maarten, van Dam, Gooitzen M., Zion, Todd C.

“…Previous interim data from a phase I study of AKS-452, a subunit vaccine comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike…”
Get full text

Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452 by Janssen, Yester F., Feitsma, Eline A., Boersma, Hendrikus H., Alleva, David G., Lancaster, Thomas M., Sathiyaseelan, Thillainaygam, Murikipudi, Sylaja, Delpero, Andrea R., Scully, Melanie M., Ragupathy, Ramya, Kotha, Sravya, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Ronca, Shannon E., Green, Freedom M., Aminetzah, Ari, Sollie, Frans, Kruijff, Schelto, Brom, Maarten, van Dam, Gooitzen M., Zion, Todd C.

“…To address the coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a…”
Get full text